Gelonghui, December 27丨Shanghai Pioneer Holdings (01345.HK) announced that recently, Chongqing Pioneer Pharmaceutical Co., Ltd., a subsidiary of the company, signed an intellectual property transfer agreement with Q3 Medical Devices Limited (Q3 Medical Devices Limited). Based on this, Chongqing Pioneer agreed to the acquisition, and Q3 Medical agreed to sell all intellectual property rights (patents and proprietary technology) owned by Q3 Medical up to the date of signing, as well as all rights in newly developed intellectual property rights in mainland China within three years after the signing date.
Q3 Medical is committed to treating lumen diseases in the human body through microintervention. The products cover blood vessels and non-blood vessels. Q3 Medical has the world's leading biodegradable technology, and its two biodegradable stents (Archimedes and Unity B) are currently the only marketed biliary and pancreatic biodegradable stents in the world. Compared with non-degradable stents, Archimedes and Unity B can eliminate secondary surgical removal, reduce the complication rate, and reduce overall treatment costs. Currently, clinical applications in the European market are rapidly increasing, showing excellent clinical value.
Q3 Medical will exclusively transfer to Chongqing Pioneer and its associated companies the right to research, develop, import, use, sell, sell, manufacture and continue to produce transferred products relating to the underlying assets in mainland China. Chongqing Pioneer and its associated companies plan to set up a factory in mainland China to develop, produce, and sell products under the above intellectual property rights. Q3 Healthcare will provide necessary services and support for technology transfer at the mainland Chinese factory.
The board of directors of the company believes that the acquisition of all intellectual property rights of Q3 Medical in mainland China and the establishment of a factory to develop, produce and sell these innovative medical products will benefit the company's future strategic transformation, that is, from a simple agent to a company that independently develops and produces innovative medical products, increasing the competitiveness of the company's products and contributing to steady business growth. Furthermore, speeding up the registration and localization of innovative products in China will help Chinese patients to use the world's most advanced medical products as soon as possible, and also reflects the social effects brought about by this acquisition.